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Abstract
Background: The steady rise in the spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB) requires rapid and reliable methods to identify resistant strains. The current
molecular methods to detect MTB resistance to second-line drugs either do not cover an extended spectrum of
mutations to be identified or are not easily implemented in clinical laboratories. A rapid molecular technique for
the detection of resistance to second-line drugs in M. tuberculosis has been developed using hybridisation analysis
on microarrays.
Methods: The method allows the identification of mutations within the gyrA and gyrB genes responsible for
fluoroquinolones resistance and mutations within the rrs gene and the eis promoter region associated with the
resistance to injectable aminoglycosides and a cyclic peptide, capreomycin. The method was tested on 65 M.
tuberculosis clinical isolates with different resistance spectra that were characterised by their resistance to ofloxacin,
levofloxacin, moxifloxacin, kanamycin and capreomycin. Also, a total of 61 clinical specimens of various origin (e.g.,
sputum, bronchioalveolar lavage) were tested.
Results: The sensitivity and specificity of the method in the detection of resistance to fluoroquinolones were 98%
and 100%, respectively, 97% and 94% for kanamycin, and 100% and 94% for capreomycin. The analytical sensitivity of
the method was approximately 300 genome copies per assay. The diagnostic sensitivity of the assay ranging from 67%
to 100%, depending on the smear grade, and the method is preferable for analysis of smear-positive specimens.
Conclusions: The combined use of the developed microarray test and the previously described microarray-based test
for the detection of rifampin and isoniazid resistance allows the simultaneous identification of the causative agents of
MDR and XDR and the detection of their resistance profiles in a single day.
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Background
Tuberculosis (TB) is a serious medical and public problem
that threatens human health worldwide. Furthermore, the
steady rise in the spread of multidrug-resistant tuberculosis
(MDR-TB) and extensively drug-resistant tuberculosis
(XDR-TB) requires rapid and reliable methods to identify
resistant strains, as early identification allows adequate
treatment, further preventing the transmission of the
dangerous agent.
However, TB caused by resistant strains is difficult
to treat, and the drug regimens are lengthy, toxic,
and significantly expensive. Ideally, the prescription of
second-line anti-TB drugs should be based on knowledge
of the causative agent’s resistance and the patient’s
treatment history. At present, the most potent drugs
include fluoroquinolones (FQs) and injectable antibiotics,
kanamycin (KAN) and capreomycin (CAP).
Approximately 80% of FQ-resistant strains bear
mutations within the quinolone resistance-determining
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region (QRDR) of the gyrA gene [1], yet it has been
increasingly reported that some FQ-resistant isolates bear
mutations in the gyrB gene. Although the contribution of
these mutations to resistance is under discussion [2,3], the
role of five mutations (D500A, N538D, N538T, T539P,
E540V) was confirmed by a DNA gyrase inhibition assay
[4-7]. Thus, including the gyrB gene as a target appears
reasonable to improve the molecular detection of FQ
resistance [8].
The most commonly reported mutations that cause
resistance to injectable aminoglycosides and CAP are
a1401g, c1402t and g1484t in the rrs gene [9]. Less
frequently, mutations within the eis promoter region and
tlyA gene are also considered to be responsible for
resistance [10,11]. It is expected that the sensitivity of KAN
resistance detection will increase from 58% to 87% if the
eis locus is included in the analysis [1]. Additionally, the
mutations in the tlyA gene are only associated with CAP
resistance [12]; these mutations are rare and are located
throughout the entire gene, making their identification
awkward.
The current molecular methods to detect MTB resistance
either do not cover an extended spectrum of mutations to
be identified [13] or are not easily implemented in clinical
laboratories, mainly due to their cost (e.g., sequencing and
pyrosequencing) [14,15].
This report describes a rapid microarray technique to
detect the resistance to FQs and second-line injectable
drugs (KAN and CAP) in MTB. This technique is the
perfect complement to the TB-Biochip test for the
analysis of rifampin/isoniazid resistance [16], which has
been used in Russia for more than 5 years. The assay
developed analyses mutations in the gyrA (codons 70-102)
and gyrB (codons 485-543) genes responsible for FQ
resistance and mutations in the rrs gene and the eis
promoter locus that are associated with the resistance
to aminoglycosides and CAP. Because of the accurate,
unambiguous identification of a wide spectrum of
relevant mutations, the uncomplicated interpretation
of the results, and the high-throughput nature, reli-
ability and reproducibility, this method can easily be
implemented in any clinical laboratory that is familiar
with PCR.
Methods
Bacterial isolates, clinical samples, DNA isolation and
microscopy
For the present study, 65 M. tuberculosis clinical isolates
were chosen. The isolates were obtained from sputum
samples collected from previously treated patients at the
Moscow Scientific and Clinical Antituberculosis Center
and two specialised antituberculosis clinics in Moscow.
M. tuberculosis strain H37Rv was used as a control for
the microbiological and genetic tests. The stored isolates
were subcultured on Lowenstein-Jensen solid medium
and incubated at 37°C for 2 to 4 weeks.
A total of 61 clinical samples (sputum, biopsy,
bronchioalveolar lavage, caseating material, urine and
cavitary walls) were obtained from patients (primary and
previously treated) attending the Research Institute for
Phthisiopulmonology, Moscow between January and
March 2012. These samples were used only for tests of
analytical sensitivity.
The clinical samples were processed according to
the international guidelines using the N-acetyl-L-cysteine-
NaOH decontamination procedure (final NaOH con-
centration: 1%). The clinical specimens were divided
into two groups: one used for smear preparation and
the other for DNA isolation. The smear grading was
performed using WHO recommendations [17].
DNA extraction from the analysed isolates and clinical
samples was performed using the “Proba-NK” DNA extrac-
tion kit (DNA-Technology Company, Russia). The DNA
concentrations were determined spectrophotometrically at
260 nm, and the DNA samples were stored at -20°C. All
isolates were analyzed by spoligotyping [18].
According to the Ethics Committees of Department of
Health of Moscow and I. M. Sechenov Moscow Medical
Academy, this research does not require ethical approval.
All samples used in this study were without any personal
information about the patients, in particular without any
ID by name, address, i.e. anonymous samples.
Drug susceptibility testing (DST)
First-line DST for rifampicin(RMP), isoniazid(INH) and
ethambutol(EMB) was performed using Bactec MGIT 960
according to the manufacturer’s instructions. Among the
65 isolates, 46 were multidrug-resistant, whereas 3 and 4
isolates were resistant to only INH and RMP, respectively;
12 isolates were sensitive (See Additional file 1: Table S1).
The resistance of the isolates to ofloxacin(OFX) was
determined by the absolute concentration method, and
the breakpoint concentrations were 2 and 10 mg/L.
Levofloxacin (LVX), moxifloxacin (MFX), KAN and
CAP MICs for all the isolates were determined using the
Bactec MGIT 960 automated system. For KAN and
CAP, 2.5 mg/L was used as the breakpoint concentration
[19]; for LVX and MFX, the concentrations were 2 mg/L
and 0.25 mg/L, respectively [20].
Oligonucleotide design
The melting temperatures were calculated, and the
secondary structures of the designed oligonucleotides were
estimated using an OligoAnalyzer (Integrated DNA
Technologies, http://eu.idtdna.com/analyzer/Applications/
OligoAnalyzer/). The lengths of the oligonucleotides
were adjusted to maintain the difference of the melting
temperatures within 2 to 3°C.
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The oligonucleotides used for immobilisation on the
biochip and the primers for amplification were synthesised
and purified as described [21]. The molecular masses of
the oligonucleotides were measured with a matrix-assisted
laser desorption ionisation–time of flight (MALDI-TOF)
mass spectrometer (Compact MALDI 4; Kratos Analytical,
Chestnut Ridge, NY) using sinapinic acid or 2-amino-5-
nitropyridine as the matrix.
Biochip design and interpretation of hybridisation results
The biochip for the detection of mutations in M.
tuberculosis leading to FQ and AMG resistance consisted
of 83 gel pads with immobilised oligonucleotides (See
Additional file 2: Table S2), 3 marker pads (M), and 2
reference gel pads without oligonucleotides for processing
the hybridisation image (Figure 1). This biochip allows the
detection of 16 and 23 mutations in the QRDR regions of
the gyrA and gyrB genes, 4 mutations in the rrs gene and
5 mutations in the promoter region of the eis gene. The 4
clusters of analysed loci consisted of 36, 33, 6 and 7 array
elements. The clusters can be subdivided into groups in
which one element contains oligonucleotides with the wild-
type sequence and the other pads contain sequences with
mutations at the same position (2-5 bp). The interpretation
of the fluorescence following the analysis was described
previously [22].
Biochip manufacture
The biochips were manufactured as described previously
[21] and assembled with 30 μL hybridisation chambers
(Biochip-IMB, LLC, Moscow, Russia). Each biochip
contained semispherical gel elements of 150 μm in
diameter placed 300 μm apart. Quality control was
performed by measuring the fluorescence of reporter
molecules on each gel element using the TestChip software
provided by Biochip-IMB, LLC.
PCR amplification
Multiplex asymmetrical PCR with universal adapters was
used to amplify a 203 bp fragment of the gyrA gene,
313 bp of gyrB, 280 bp of rrs and 176 bp of eis. The
primers used in the multiplex PCR are listed in
Additional file 3: Table S3. The 30 μl reaction
contained 15 μl Qiagen Multiplex Mastermix, 8 μM
fluorescently labelled dUTP-ImD#49 (Biochip-IMB,
LLC, Moscow), 100 μM gyrA and rrs primers,
50 μM gyrB and eis primers, 50 μM Uni-F and
2 mM of Uni-R primers, and 3 μl DNA sample. The
cycling conditions were as follows: denaturation at
95°C for 5 min; 40 cycles of denaturation at 95°C for
30 s, annealing at 64°C for 30 s and extension at 72°C for
30 s; then 40 cycles of denaturation at 95°C for 30 s,
annealing at 50°C for 30 s and extension at 72°C for 30 s;
and a final extension step at 72°C for 5 min.
Hybridisation on the biochip and registration of the
results
The hybridisation mixtures were prepared by adding 10 μL
of the PCR mixtures to 20 μL 1.5 M guanidine thiocyanate
(GuSCN), 0.075 M HEPES (pH 7.5), and 7.5 mM EDTA.
The biochip hybridisation chamber was filled with the
mixture, and the assembly was incubated for 10 to
16 h at 37°C. The chamber was then removed, and the
microarray surface was washed twice (approximately 30 s
each) with water at 37°C and air-dried. The fluorescent
pattern of the biochips was registered using a fluorescence
analyser setup and specialised software “ImaGeWare”
(Biochip-IMB, LLC).
Sequencing
The fragments of the genes that determine resistance (gyrA,
gyrB, rrs, and eis) were amplified using the corresponding
primers (See Additional file 3: Table S3) and then subjected
to dideoxy-sequencing using one of the terminal primers
and the ABI PRISM® BigDye™ Terminator v. 3.1 (Applied
Biosystems, Foster City, CA, USA) followed by analysis
with the 3730 automatic DNA analyzer.
Results
Determination of MICs using Bactec MGIT 960
Among the 65 M. tuberculosis clinical isolates that were
obtained from sputum samples, 42 (65%) were resistant
to OFX, and most of the OFX-resistant strains were also
resistant to LVX (n = 37) and MFX (n = 40), see Table 1.
There was a strong correlation between the minimum
inhibitory concentrations (MICs) of both fluoroquinolones.
The MIC values for LVX and MFX were 4-16 mg/L and
0.5-4 mg/L, respectively, for many of the strains. One
isolate was tolerant to 32 mg/L LVX and 8 mg/L MFX
(the maximal MIC that was found).
Resistance to KAN was detected in 34 (52%) isolates,
with 18 strains demonstrating a high level of resistance
to KAN (MIC >80 mg/L, see Table 2) and 17 also
showing resistance to CAP (the MICs varied from 2.5
to 20 mg/L). The strains resistant to low and medium
concentration of KAN (MIC: 2.5-10 mg/L) were also
sensitive to CAP.
Detection of mutations by biochip analysis
The mycobacterial target DNA loci responsible for the
emergence of resistance to FQs, AMG and CAP were
analysed by hybridisation on the developed microarray.
The procedure consisted of two steps: (1) a multiplex PCR
of the gyrA, gyrB, and rrs gene segments and the eis
promoter locus and (2) hybridisation of fluorescently
labelled single-stranded PCR products on the microarray.
The hybridisation pattern corresponding to M.
tuberculosis H37Rv wild-type DNA is shown in Figure 1B.
Within each group of gel elements, the strongest
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fluorescence signal corresponds to the gel pad containing
a probe with the wild-type sequence. Hybridisation of
a sample bearing a gyrA A90V mutation is shown in
Figure 1C for comparison. The arrows point to pads on
which the amplified DNA hybridised with oligonucleotide
probes bearing mutant sequences. In group 90, the
maximal signal corresponds to the oligonucleotide
probe with a sequence leading to a A90V mutation.
The analysis of 94 groups indicated that the DNA
contains a S95T polymorphism.
Analytical sensitivity
The performance of the biochip-based test was evalu-
ated using 61 clinical samples characterised by smear
microscopy; the results are shown in Table 3. The
overall concordance with the smear microscopy for
the biochip-based assay ranged from 100% with high
AFB counts (3+) to 67% (1+). There were no differences
in the sensitivity of the assay between the samples from
different clinical material and collected from patients with
newly detected TB and those previously treated for TB.
The analytical sensitivity of this method was estimated
by assaying 10-fold serial dilutions of the purified genomic
DNA of M. tuberculosis strain H37Rv; four replicates were
used for each dilution. The hybridisation results obtained
with 300 genomic equivalents were unambiguous.
Correlation of phenotypic DST with molecular assays
Data obtained from the biochip analysis and DST data for
each strain are listed in Additional file 1: Table S1, and
comparative summary is presented in Tables 1, 2 and 4.
gyrA mutations conferring FQ resistance (38 of 42
strains) were found in 90% of the samples. No mutations
in the QRDR regions of the gyrB were identified both by
the biochip and the sequencing of DNA fragments
contained from 475 to 585 codons. The mutation
frequencies correlate with the previously reported data
[8]: D94G and A90V were most frequently found in 23
strains. All 12 strains with D94G were resistant to LVX
(MIC: 4-16 μg/mL), in contrast to 6 strains with D94A,
which were sensitive to LVX (MIC: 0.5-2 μg/mL). The
S95T polymorphism, which does not lead to resistance,
was detected in 17 of 23 sensitive to FQ strains.
Figure 1 Analysis of Mycobacterium tuberculosis drug
susceptibility by hybridisation on a biochip. (A) The scheme of
the biochip for hybridisation. The subgroups are depicted as boxes.
Each subgroup corresponds to a single variable amino acid position
or variable nucleotide. One gel element within each subgroup
contained an oligonucleotide matching the wild-type sequence
(bold circles). (B) Hybridisation of a wild-type DNA sample on the
biochip. (C) Hybridisation of a DNA sample containing the following
mutations indicated by arrows: gyrA (S91P, TCG > CCG) and gyrA
(S95T, AGC > ACC).
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A strain with a rare G88C mutation [23,24] was resistant
to all three FQs, and the rare mutation H70R [25] was
found in three strains only in combination with G88A or
A90V. Two more strains with double mutations in
gyrA carried A90V with D94 substituted with G or Y.
A90V +D94G showed higher resistance levels compared
to the strains with single A90V or D94G mutations. The
MICs of the A90V +D94Y strain were close to those of
the A90V strains.
Of 41 strains, 3 had mutations in the gyrB gene, with
only an S95T substitution in gyrA. Sequencing for
confirmation of the biochip data included a fragment
from 59 to 132 codons of gyrA. All three strains were
resistant to 2 μg/mL OFX. The strain with D500H
was also resistant to LVX and MFX, which was
shown in an earlier study [3]. Additionally, we found
a strain bearing R485H that was resistant to OFX and
sensitive to LVX and MFX. The mutation R485H was
previously found in an OFX-resistant strain [14]. The
third strain with the well-characterised N538D mutation
was also resistant to MFX.
Therefore, mutations were detected in 41 of the 42
strains resistant to FQs. In 24 sensitive strains, no
false-positive results were obtained.
Mutations were found in 33 of 34 KAN-resistant
strains: an rrs(a1401g) mutation was found in 17, with
mutation in the eis promoter region in 16 strains. The
eis(g-10a) mutation was found in 10 strains. With regard
to KAN, no mutations were found either by biochip
analysis or sequencing in 30 sensitive and one resistant
strain. The strains with rrs(a1401g) mutations possessed a
Table 2 Correlation of detected mutations in the rrs and





MIC Bactec MGIT 960 (mg/L)
KAN CAP
rrs (a1401g) 17 >80 3-20
eis (g-10a) 10 5 to >80 0.6 to 2.5
eis (c-12t) 2 1.3 to 5 1.3
eis (c-14t) 2 20 1.3
1 0.63 1.3
eis (g-37t) 3 10 to 20 1.3 to 2.5
No mutation 29 0.3 to 2.5 0.6 to 2.5
1 5 1.3
(H37Rv) 2.5 2.5
The MICs considered to reflect resistance are highlighted in bold.
Table 1 Correlation of the detected mutations in the gyrA and gyrB genes with phenotypic DST
Mutation No. of
isolates
Resistance (mg/L) MIC Bactec MGIT 960 (mg/L)
gyrA gyrB OFX LVX MFX
D94G wt 1 10 8 2
D94Ga wt 12 2 to 10 4 to 16 2
D94Aa wt 6 2 2 0.5 to 2
D94Na wt 1 2 8 4
D94Ha wt 1 10 4 2
D94Ya wt 1 2 4 1
A90Va wt 9 2 to 10 2 to 8 0.5 to 2
S91Pa wt 1 2 2 1
G88C wt 1 10 8 4
A90V + D94Ga wt 1 10 >32 8
A90V + D94Ya wt 1 2 2 1
H70R + G88Aa wt 2 2 2 1 to 2
H70R + A90Va wt 1 2 8 2
S95T D500H 1 2 4 0.5
S95T R485H 1 2 1 0.25
S95T N538D 1 2 2 0.5
S95T wt 1 2 1 0.125
S95T wt 17 S ≤0.5 ≤0.25
wt wt 6 S ≤1 ≤0.25
wt wt (H37Rv) S 0.5 0.125
aadditional mutation S95T.
Resistance to OFX was detected by the absolute concentration method. For LVX and MFX, resistance was defined as LVX (>2 mg/L) and MFX (>0.25 mg/L). The
MICs considered to reflect resistance are highlighted in bold.
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high level of KAN resistance (MIC >80 μg/mL) and
were also resistant to CAP, with MICs ranging from
3 to 20 μg/mL.
The strains with eis mutations were sensitive to CAP
and resistant to KAN, with MICs varying over a wide
range (0.63 to 20 μg/mL). Although strains with eis
(g-10a) and (g-37t) mutations were KAN resistant (n = 10
and 3, respectively), we also found KAN-sensitive strains
with the same mutations. The variation in the KAN MICs
for strains with the same mutation could be an unknown
effect of the genetic background.
Discussion
A rapid molecular technique to detect resistance to
second-line drugs in MTB using hybridisation analysis on
microarrays was developed in this study. The method
allows the identification of mutations within the gyrA and
gyrB genes (the regions responsible for FQ resistance), and
mutations within the rrs gene and the eis promoter region
associated with the resistance to injectable aminoglycosides
and a cyclic peptide, capreomycin.
An original primer set was designed to obtain all four
specific amplicons using multiplex PCR. The resulting
PCR products were fluorescently labelled, predominantly
single stranded, and were used for the hybridisation analysis
on the microarray.
The oligonucleotide probes immobilised on the micro-
array were designed to identify nucleotide substitutions
in codons 70, 74, 80, 88, 90, 91, 94, 95 and 102 for the
gyrA gene, in 485, 500, 509, 525, 533, 538, 539, 540, and
543 codons for the gyrB gene, at positions 1401, 1402,
and 1484 from transcription start site for the rrs gene
and within the -10 and -35 promoter regions of the eis
gene. The developed set of primers is theoretically
capable of providing a sensitivity of 96% in the detection
of fluoroquinolone resistance [14] and 87% and 55% for
KAN and CAP resistance, respectively [1].
The role of a number of the gyrB and eis mutations
with regard to the resistance phenotype remains under
discussion. Only five mutations in gyrB gene (D500A,
N538D, N538T, T539P, E540V) were confirmed for FQ
resistance by a DNA gyrase inhibition assay [4-7].
Nevertheless, we extended a spectrum of identified gyrB
mutations since one cannot exclude possibility that
disputable mutations could alter the resistance phenotype
in combination with other mutations, as was reported for
GyrA (A74S) in combination with S95T [3] and T80A
with mutations in codon 90 of the gyrA gene [4,26,27].
A large number of identified mutations does not lead
to the decrease of analytical sensitivity. An updated
data concerning contribution of particular mutation
to the resistance will demand only adjusting the
threshold in software for determination of this mutation
on a chip, without redesigning the microarray and PCR
primer system.
The performance of the method in revealing resistance
in MTB was examined using 65 clinical isolates that
differed in their resistance spectra. 46 of them were
MDR, 3 and 4 strains were monoresistant to RMP and
INH, correspondingly. Beijing genotype was predominant
among all strains with strong difference between MDR
and non-MDR strains: 74% versus 50%.
26 of 28 XDR strains were correctly identified by biochip
analysis (sensitivity - 93%). Two MDR strains resistant to
only FQs were identified as XDR, both bearing mutations
in eis gene. The specificity of XDR detection was 95%.
Among the FQ-resistant strains, mutations in gyrA
codons 90, 91, and 94 were observed in 86% cases
(36 of 43). Four isolates (9%) contained substitutions
within codons 70 and 88 (the gyrA gene), and two
isolates had mutations in the gyrB gene only (D500H,
and N538D). One more strain bearing R485H substitution
in gyrB gene was resistant to OFX and sensitive to
LVX and MFX; however, the role of this mutation in
FQ resistance was not confirmed by a gyrase assay
[2,3]. Five strains with double mutations in gyrA were
detected. They could be either true double mutant,
either the result of heteropeaks due to the presence
of different clones [8]. However, the spoligotyping revealed
the unambiguous pattern for every strain. The sensitivity
and specificity of the method relating to FQ resistance
were 98 and 100%, respectively.
Table 3 Performance of the biochip-based assay
depending on the concentration of acid-fast bacilli in










3+ 19 19 0 100%
2+ 13 10 3 77%
1+ 12 8 4 67%
1-12 bacilli/
300 fields
8 6 2 75%
negative 9 1 8 11%
Table 4 Performance of biochips in comparison with DST
Biochip
resulta
Number of isolates with the indicated result
OFX LVX MFX KAN CAPb XDR
R S R S R S R S R S R S
R 41 0 24 17 40 1 33 2 16 1 26 2
S 1 23 0 24 0 24 1 29 0 48 2 37
Sensitivity (%) 98 100 100 97 100 93
Specificity (%) 100 59 98 94 94 95
a - R, isolates with mutations in gyrA, gyrB (FQ), rrs(KAN and CAP), eis(KAN);
S, isolates without mutations.
b - Isolates with mutations in eis were considered sensitive in biochip analysis.
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It was found that the a1401g mutation in the rrs gene
correlates with the resistance to KAN and CAP in MTB,
as was previously demonstrated [1,15].
Most of the strains bearing eis mutations were resistant
to KAN (16 from 18) yet sensitive to CAP, but we also
found two KAN-sensitive strains with eis(c-12t) (1 of 2
strains) and eis(c-14t) (1 of 3 strains) mutations. From the
published data, eis(c-12t) is more often found in sensitive
strains than in resistant strains [1,10,15,28], with only one
report indicating that all 4 strains with this mutation
were resistant to KAN [29]. Most of the strains with
eis(c-14t) were KAN resistant [1,10,29], and only one
of approximately ten strains were found to be sensitive in
two reports [15,28]. In our study, eis(g-10a) was the second
most frequent mutation found in the KAN-resistant
strains (29%, n = 10), and all strains with this mutation
were resistant, though the KAN MIC values varied widely.
In previous studies, all the strains [10,29] or most of the
strains [1] with this mutation were resistant to KAN,
whereas Engstrom [15,28] reported that 85% of the strains
were sensitive. We observed that the eis(g-37t) mutation
was quite rare (9%, n = 3) but always was associated with
resistance to KAN. Such correlation is in full accordance
with the conclusions of other researchers [1,10,15,28,29].
Therefore, the involvement of mutations in the eis
promoter region in the development of resistance to
KAN remains unclear and requires additional statistically
valid tests.
The sensitivity of the method concerning KAN resistance
was high (96%), and the test was specific. The sensitivity for
CAP was 100% because all 17 isolates with the rrs(a1401g)
mutation tolerated CAP at concentrations of 3-10 μg/mL.
The analytical sensitivity of the method, or the minimal
amount of bacterial genome equivalents that can be
reliably identified by the technique, was 300 per
assay. The obtained value allowed us to suppose that
clinical samples could be analysed using the method in
addition to isolates. To obtain experimental evidence,
61 clinical specimens of various origin (e.g., sputum,
bronchioalveolar lavage) were tested. The diagnostic
sensitivity of the assay ranged from 67 to 100% and
depended on the number of mycobacterial cells used
per analysis. This sensitivity depending on sputum
grade was comparable to Genotype® MTBDRPlus kit
[30]. However, the performance of the method in smear
negative samples was found to be insufficient. So, to be
used as a direct method, the analysis of smear-positive or
culture-positive samples for drug resistance profiling
could be preferable.
The developed approach fits easily in institutions that
are already using biochip-based kits for M. tuberculosis
DST [16]. Moreover, the assay can be applied to any
laboratory utilizing molecular genetic techniques for
analysis of tuberculosis causative agent, by addition of
simple and inexpensive (less than 10 k US dollars)
fluorescence analyzer equipped with specialized software.
On the other part, the method requires fully equipped
DNA manipulation/PCR laboratory and trained staff to
perform the test.
Conclusions
In conclusion, we developed a sensitive and specific
microarray-based technique for the identification of
resistance to FQ and the second-line injectable
aminoglycosides KAN and CAP in Mycobacterium
tuberculosis. The knowledge of the MTB resistance
spectrum is important for the effective treatment of
MDR- and XDR-TB. The developed microarray is
considered to be the perfect complement for the
commercially available diagnostic system TB-Biochip
(MDR) [22]. The combined use of the developed
microarray test and the TB-Biochip (MDR) allows the
simultaneous identification of the MDR and XDR
causative agents and the detection of their resistance
profiles in a single day.
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